Bioequivalence Study of 5 mg Aripiprazole Tablets, Manufactured by PT. Amarox Pharma Global (Aripiprazole) in Comparison with the Innovator’s Tablets (Abilify®), Manufactured by Korea Otsuka Pharmaceutical Co., Ltd., Gyeonggi-do, Korea, under Authorization of Otsuka Pharmaceutical Co., Ltd., Japan, Imported by PT. Otsuka Indonesia, Malang, Indonesia
Tahapan Penelitian : Complete
Sponsor:
PT. Amarox Pharma Global
Mitra Pelaksana:
Econolab
No Registry
INA-E5M01FS
Tanggal Input Registry : 09-02-2024
| Tracking Information | |
|---|---|
| Tanggal Antisipasi Studi | 14-02-2020 |
| Outcome Primer | AUC-t and Cmax |
| Outcome Skunder | AUC0-t, Tmax, T1/2 |
| Descriptive Information | |
| Judul Penelitian Popular | Bioequivalence Study of 5 mg Aripiprazole Tablets, Manufactured by PT. Amarox Pharma Global (Aripiprazole) in Comparison with the Innovator’s Tablets (Abilify®), Manufactured by Korea Otsuka Pharmaceutical Co., Ltd., Gyeonggi-do, Korea, under Authorization of Otsuka Pharmaceutical Co., Ltd., Japan, Imported by PT. Otsuka Indonesia, Malang, Indonesia |
| Judul Penelitian Ilmiah | Bioequivalence Study of 5 mg Aripiprazole Tablets, Manufactured by PT. Amarox Pharma Global (Aripiprazole) in Comparison with the Innovator’s Tablets (Abilify®), Manufactured by Korea Otsuka Pharmaceutical Co., Ltd., Gyeonggi-do, Korea, under Authorization of Otsuka Pharmaceutical Co., Ltd., Japan, Imported by PT. Otsuka Indonesia, Malang, Indonesia |
| Jenis Penelitian | Interventional |
| Intervensi | Single dose of one tablet of 20 mg Aripiprazole (Aripiprazole), Manufactured PT Amarox Pharma Global |
| Jumlah Subyek Penelitian | 18 |
| Recruitment Information | |
| Eligibility Criteria | Inclusion Criteria: Willing to use contraception (condoms) when intercourse with spouse during the study. Able to participate, communicate well with the investigators and agree to sign an informed consent; Healthy male/female subjects as determined by the medical screening assessments; Aged 44-55 years of age; Body mass index (BMI) is in the range of 18-25 kg/m²; Systolic blood pressure:100-120 mmHg; Diastolic blood pressure: 60-80 mmHg; Pulse rate 60-90 bpm; Normal electrocardiogram (ECG).Exclusion Criteria: Pregnant or lactating women (urinary pregnancy test were applied to female subjects when screening and just before taking the test or innovator drug); Known hypersensitivity or contraindication to the study drug; intake of any prescription drug or non-prescription drug/food supplement/herbal medicine within 7 days of this study’s first dosing day; History of any bleeding or coagulation disorders; Any surgical or medical condition (present or history) which might significantly alters the absorption, distribution, metabolism or excretion of the study drug, e.g. gastrointestinal diseases including gastric or duodenal ulcers or history of gastric surgery; A donation or loss of 300 mL (or more) of blood within 3 months before this study’s first dosing day; A positive Hepatitis B surface antigen (HBsAg), HCV, HIV test result; History of drug or alcohol abuse within 12 months prior to this study; Heavy Smoker (more than 10 cigarettes a day); Clinically have significant bleeding within 3 months prior to the study; Participation in a previous study within 3 months of this study’s first dosing day; Subject with historical medication of dystonia (personal or family); Subject with neuroleptic agent usage; A positive antibody Corona virus (Covid-19) test result for second group (Group 2). |
| Administrative Information | |
| Nomor Persetujuan Etik | KET-808/UN2.F1/ETIK/PPM.00.02/2019 |
| Nomor Persetujuan Material Transfer Agreement | Not applicable |
| Nomor Persetujuan Pelaksanaan Uji Klinik | PPUK/PPUB number |
| Other Study ID Numbers | PRO-243/19/ECL |
| Contact Person | Ni Made Dwi Wulandari |